Abstract

The Flow Cytometry and Cell Sorting Facility was established by the Cancer Center in 1980. It has been continuously approved and funded by the NCI Core Support Grant since 1981. Jonni Moore, PhD, has directed the Flow Cytometry and Cell Sorting Facility since 1990. Dr. Moore has a doctorate in immunology and over fifteen years of flow cytometry experience, and serves as an expert consultant to manufacturers of flow cytometry equipment (i.e., Becton Dickinson) and to other flow cytometry laboratories (e.g., SmithKline Beecham, Merck). Charles Pletcher, MCI, Technical Director has been with the Facility since 1987. The Facility has grown tremendously during the current project period. This has resulted from major operational improvements, during acquisition of newer technology, and recruitment of expert staff. With the equipment purchased during the current project period (FACSVantage and FACSCalibur), it now possesses capabilities equal to those of the most sophisticated flow cytometry facilities. Overall usage of the core has increased 67% during the current project period. Usage by Cancer Center members with peer-reviewed funding is 77% and usage by all Cancer Center members is 86% of total facility usage.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-27
Application #
6573823
Study Section
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
2002
Total Cost
$228,564
Indirect Cost

  Institution

Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications